Clinical Trials Browser

Phase EARLY_PHASE1 × lenvatinib × 90 days × Clear all

NCT05041153 2026-01-12

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

Phase EARLY_PHASE1 Recruiting

Gastrointestinal

Advanced Gastric Adenocarcinoma